Jan 11, 2023 / 06:30PM GMT
Daniel Wolle - J.P. Morgan - Analyst
Good morning, my name is Daniel Wolle. I'm one of the analysts on the SMID Cap team at J.P. Morgan. It's my pleasure to introduce Steve Hurly from LAVA Therapeutics. (Conference Instructions) Without further ado, Steve.
Steve Hurly - LAVA Therapeutics N.V. - CEO
Thank you, Daniel, and thank you to J.P. Morgan for the opportunity to participate in this wonderful conference. My name is Steve Hurly, I'm the President and Chief Executive Officer of LAVA Therapeutics. I appreciate everybody's time today. Before I begin, this is our forward-looking statements. We'll be making forward-looking statements. Please read thoroughly before making any investment decisions.
So we at LAVA Therapeutics are focused on developing next-generation cancer therapeutics. I'm sure you're all quite familiar with the first generation of T-cell engagers, CD3 engagers. Looking at a broad mixed bag of cells, our approach is to utilize the same engager approach over that subpopulation of T-cells Vgamma9 Vdelta2 family inside of the gamma delta T
LAVA Therapeutics NV at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers